NRAS mutant melanoma – undrugable?

por Posch, Christian, Ortiz-Urda, Susana
Publicado 2013

Melanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradox

por Goldenberg, Alina, Vujic, Igor, Sanlorenzo, Martina, Ortiz-Urda, Susana
Publicado 2015

MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and ‘wild type’ melanomas

por Posch, Christian, Sanlorenzo, Martina, Ma, Jeffrey, Kim, Sarasa T., Zekhtser, Mitchell, Ortiz-Urda, Susana
Publicado 2018

Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma

por Curl, Patti, Vujic, Igor, van ‘t Veer, Laura J., Ortiz-Urda, Susana, Kahn, James G.
Publicado 2014

Correction: Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma

por Curl, Patti, Vujic, Igor, van ‘t Veer, Laura J., Ortiz-Urda, Susana, Kahn, James G.
Publicado 2015

Cutaneous CD56(+) T-cell lymphoma developing during pembrolizumab treatment for metastatic melanoma

por Zheng, Yixuan James, Lee, Albert, Pincus, Laura, Ho, Wilson, Vujic, Marin, Ortiz-Urda, Susana
Publicado 2018

Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients

por Posch, C, Weihsengruber, F, Bartsch, K, Feichtenschlager, V, Sanlorenzo, M, Vujic, I, Monshi, B, Ortiz-Urda, S, Rappersberger, K
Publicado 2014

Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo

por Posch, Christian, Moslehi, Homayoun, Sanlorenzo, Martina, Green, Gary, Vujic, Igor, Panzer-Grümayer, Renate, Rappersberger, Klemens, Ortiz-Urda, Susana
Publicado 2016

Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment

por Feichtenschlager, Valentin, Zheng, Yixuan James, Ho, Wilson, Chen, Linan, Callanan, Ciara, Chen, Christopher, Lee, Albert, Ortiz, Jose, Rappersberger, Klemens, Ortiz-Urda, Susana
Publicado 2023

Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma

por Posch, C, Cholewa, BD, Vujic, I, Sanlorenzo, M, Ma, J, Kim, ST, Kleffel, S, Schatton, T, Rappersberger, K, Gutteridge, R, Ahmad, N, Ortiz/Urda, S
Publicado 2015

Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer

por Vujic, Igor, Sanlorenzo, Martina, Posch, Christian, Esteve-Puig, Rosaura, Yen, Adam J., Kwong, Andrew, Tsumura, Aaron, Murphy, Ryan, Rappersberger, Klemens, Ortiz-Urda, Susana
Publicado 2014

Mutant NRAS(Q61) shares signaling similarities across various cancer types – potential implications for future therapies

por Vujic, Igor, Posch, Christian, Sanlorenzo, Martina, Yen, Adam J., Tsumura, Aaron, Kwong, Andrew, Feichtenschlager, Valentin, Lai, Kevin, Arneson, Douglas V., Rappersberger, Klemens, Ortiz-Urda, Susana M.
Publicado 2014

Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells

por Vujic, Igor, Sanlorenzo, Martina, Esteve-Puig, Rosaura, Vujic, Marin, Kwong, Andrew, Tsumura, Aaron, Murphy, Ryan, Moy, Adrian, Posch, Christian, Monshi, Babak, Rappersberger, Klemens, Ortiz-Urda, Susana
Publicado 2016

The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II...

por Algazi, A P, Cha, E, Ortiz-Urda, S M, McCalmont, T, Bastian, B C, Hwang, J, Pampaloni, M H, Behr, S, Chong, K, Cortez, B, Quiroz, A, Coakley, F, Liu, S, Daud, A I
Publicado 2015

The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma

por Sanlorenzo, Martina, Vujic, Igor, Esteve-Puig, Rosaura, Lai, Kevin, Vujic, Marin, Lin, Kevin, Posch, Christian, Dimon, Michelle, Moy, Adrian, Zekhtser, Mitchell, Johnston, Katia, Gho, Deborah, Ho, Wilson, Gajjala, Abhinay, Oses Prieto, Juan, Burlingame, Alma, Daud, Adil, Rappersberger, Klemens, Ortiz-Urda, Susana
Publicado 2018